Detail akcie Septerna Rg online

Business Summary: Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Septerna Inc revenues increased from $863K to $21.8M. Net loss decreased 25% to $38.1M. Revenues reflect GPCR segment increase from $370K to $21.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$9.13 to -$0.87.